Adalimumab
DrugWikipedia
103
MENTIONS
59
EPISODES
54
PODCASTS
Search complete. 103 mentions across 59 episodes found for "Adalimumab".
Sep 14, 2026
Michael GregerHOST
In the irritable bowel syndrome chapter, I explore the mystery of open label placebos, atypical food allergies like alpha gal syndrome, and food sensitivities like gluten, as well as covering the gut microbiome, including fecal transplants, FODMAP diets, and glutamine supplements.
Michael GregerHOST
In the inflammatory bowel disease chapter, I cover berberine supplements and biologic drugs like Humira, in addition to everything else you need to know about Crohn's disease and ulcerative colitis.
Michael GregerHOST
In the nerve pain chapter, I relay concerns about gabapentin-type drugs, fighting fire with fire with the chili pepper compound capsaicin, uh, the pros and cons of cannabis, acetylcarnitine supplements, the importance of butyrate, how to prevent withdrawal symptoms when stopping antidepressants, instances where evidence-based medicine can lead us astray, and critiques of both sides of the vaccine efficacy debate.
Michael GregerHOST
In the ischemic pain chapter, I convey Dr. Katz's parable of the tiny parachute to explain why some randomized control trials require a double take.
Neha AgrawalGUEST
HIV-associated metabolic disorder to promote Egrifta and Serostim for our long-term patients with HIV.
Neha AgrawalGUEST
We just passed a hydrodinitis supertiva CPA to focus on Cosentix and Humira prescribing.
Neha AgrawalGUEST
We also have an osteoporosis CPA where we're focusing on channeling patients that need those injectable osteoporosis medications to our in-house endocrinologist.
Neha AgrawalGUEST
And so those are some other strategies we have been using to really bring in that revenue from our specialty legacy pharmacies.
Hannah StanleyHOST
And
Raj DasguptaGUEST
let's say now you're not just Hannah, you're Hannah with rheumatoid arthritis, you're on a TNF inhibitor like Humira, your immune system's not solid.
Raj DasguptaGUEST
Yeah, it all changes, you know? So that's why...
Raj DasguptaGUEST
I want to make sure that people don't get confused with this from treatment.
Wendy Netter EpsteinGUEST
They're, they're much larger, they're more complex.
Wendy Netter EpsteinGUEST
They're made using living cells, things like, you know, Humira or, or mo- many modern cancer drugs.
Wendy Netter EpsteinGUEST
And because they're so complex, the follow-on isn't called a generic, it's called a biosimilar.
Wendy Netter EpsteinGUEST
So in this case, FDA used to require new trials for biosimilars because, you know, they, they weren't chemically identical.
Katrina JohnsonGUEST
Biosimilar adoption is low primarily because the incentive structure has not historically rewarded switching.
Katrina JohnsonGUEST
So the originator biologic Humira, for example, generates large rebates for the PBM.
Katrina JohnsonGUEST
A biosimilar may cost the plan less net-net, but the rebate the PBM collects on the biosimilar is lower, sometimes significantly lower.
Katrina JohnsonGUEST
So in a retained rebate model, the PBM has a financial incentive to keep the originator on the preferred tier, even when the biosimilar would save the plan money.
Katrina JohnsonGUEST
Um, and we really like to, to put these stopgaps in place early on because as you hire new employees, they would be more used to this kind of program.
Katrina JohnsonGUEST
And when both conditions exist, biosimilar adoption improves materially.
Andy RodriguezHOST
The Humira biosimilar situation is the clearest example.
Andy RodriguezHOST
Humira went off patent in twenty twenty-three, so there's now more than twenty different FDA-approved biosimilars.
Wendy Netter EpsteinGUEST
They're more complex.
Wendy Netter EpsteinGUEST
They're made using living cells, things like Humira or many modern cancer drugs.
Wendy Netter EpsteinGUEST
And because they're so complex, the follow-on isn't called a generic.
Wendy Netter EpsteinGUEST
It's called a biosimilar.
Omar AliHOST
And I feel like they may have to rewind the podcast and listen to this bit again.
Omar AliHOST
But when I think, and I remember when the buy similar to Humira came along, across the globe, or across Europe, at least, everyone jumped, whichever buy similar was the cheapest.
Omar AliHOST
All the payers jumped on that for obvious reasons.
Omar AliHOST
In the US, the biosimilars that won were the most expensive ones because they were able to offer higher rebate to the middlemen or the PBMs or what have you.
JP ErricoHOST
And, you know, things like Ubrel-V and Amovig and that they were coming along.
JP ErricoHOST
And that everybody anticipated that those products were going to be priced by the pharmaceutical companies equivalently to things like the TNF-alpha antibodies, like Enbrel and Remicade and Humira at $30,000 a year.
JP ErricoHOST
And there was great fear among the insurance companies that that's where these pharmaceutical companies were going to price it and that they were going to end up having to write humongous checks.
JP ErricoHOST
And two things happened.
JP ErricoHOST
And the pharmaceutical companies do this all the time.
JP ErricoHOST
In fact, Novartis, not to get us off topic here, Novartis came to the market with the first bio-equivalent to the...
JP ErricoHOST
Humira, Enbrel, Remicade, TNF Alpha antibody, which sell for $30,000 in the United States.
JP ErricoHOST
Meanwhile, in Denmark, it's $300.
Dave WallaceGUEST
Yes, there are barriers to entry for a lot of companies, but there still are quite a few players in biosimilars.
Dave WallaceGUEST
And it was interesting to hear him talk about that, that he was saying as Sandoz are expanding into this kind of wider universe of products, you're not going to see all of these biosimilars attracting the kind of five to ten competitors that you might see for some of the big biosimilar LOEs that we've seen in the last few years, you know, like your Humira's, like your Stellara's.
Dave WallaceGUEST
So they're obviously anticipating different levels of competition across the portfolio for different products.
Dave WallaceGUEST
It's going to be really interesting to see whether they can make the most of some of those perhaps slightly more niche
Neisha BerryHOST
Cindy had arthritis in the joint of her hand due to Crohn's disease.
Neisha BerryHOST
She tried Humira and Meloxicam, Remicade.
Neisha BerryHOST
Oh gosh, those are awful meds.
Neisha BerryHOST
Ended up in the ER with an antibody reaction.
49 more episodes mention Adalimumab.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.